Compare SUVEN LIFE with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PFIZER SUVEN LIFESCIENCES/
PFIZER
 
P/E (TTM) x 5.0 39.4 12.8% View Chart
P/BV x 0.7 6.7 11.2% View Chart
Dividend Yield % 3.1 0.5 601.7%  

Financials

 SUVEN LIFESCIENCES   PFIZER
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
PFIZER
Mar-19
SUVEN LIFESCIENCES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3383,840 8.8%   
Low Rs1692,080 8.1%   
Sales per share (Unadj.) Rs52.1455.0 11.5%  
Earnings per share (Unadj.) Rs6.893.8 7.3%  
Cash flow per share (Unadj.) Rs8.6109.4 7.8%  
Dividends per share (Unadj.) Rs1.5022.50 6.7%  
Dividend yield (eoy) %0.60.8 77.8%  
Book value per share (Unadj.) Rs65.3658.2 9.9%  
Shares outstanding (eoy) m127.2845.75 278.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.96.5 74.8%   
Avg P/E ratio x37.131.6 117.6%  
P/CF ratio (eoy) x29.627.1 109.3%  
Price / Book Value ratio x3.94.5 86.4%  
Dividend payout %22.024.0 91.5%   
Avg Mkt Cap Rs m32,272135,420 23.8%   
No. of employees `0001.12.6 41.1%   
Total wages/salary Rs m6613,238 20.4%   
Avg. sales/employee Rs Th6,132.27,911.4 77.5%   
Avg. wages/employee Rs Th611.11,230.9 49.6%   
Avg. net profit/employee Rs Th803.51,630.7 49.3%   
INCOME DATA
Net Sales Rs m6,63520,815 31.9%  
Other income Rs m2421,674 14.5%   
Total revenues Rs m6,87722,489 30.6%   
Gross profit Rs m1,6045,712 28.1%  
Depreciation Rs m221714 31.0%   
Interest Rs m3873 51.7%   
Profit before tax Rs m1,5876,599 24.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7182,309 31.1%   
Profit after tax Rs m8694,291 20.3%  
Gross profit margin %24.227.4 88.1%  
Effective tax rate %45.235.0 129.3%   
Net profit margin %13.120.6 63.6%  
BALANCE SHEET DATA
Current assets Rs m6,23227,167 22.9%   
Current liabilities Rs m1,4908,917 16.7%   
Net working cap to sales %71.587.7 81.5%  
Current ratio x4.23.0 137.3%  
Inventory Days Days8668 127.5%  
Debtors Days Days8330 274.4%  
Net fixed assets Rs m4,0438,862 45.6%   
Share capital Rs m127458 27.8%   
"Free" reserves Rs m8,18329,656 27.6%   
Net worth Rs m8,31030,113 27.6%   
Long term debt Rs m1825 71.2%   
Total assets Rs m10,38939,400 26.4%  
Interest coverage x43.191.5 47.1%   
Debt to equity ratio x00 258.0%  
Sales to assets ratio x0.60.5 120.9%   
Return on assets %8.711.1 78.8%  
Return on equity %10.514.2 73.4%  
Return on capital %19.522.1 88.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,622428 1,312.6%   
Fx outflow Rs m1,799786 228.8%   
Net fx Rs m3,822-358 -1,067.4%   
CASH FLOW
From Operations Rs m356978 36.3%  
From Investments Rs m-279351 -79.3%  
From Financial Activity Rs m-225-1,099 20.5%  
Net Cashflow Rs m-148231 -64.2%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.7 154.0%  
Shareholders   37,287 85,207 43.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ASTRAZENECA PHARMA  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 7, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS